Non-White Patients May Be More Likely to Be Excluded From Alzheimer ’s Disease Trials

This study is an ongoing 240-week, placebo-controlled, randomized phase 3 trial of an anti-Aβ monoclonal anti body in older adults with preclinical AD. Specifically, the researchers looked at the recruiting and screening processes for 5,107 White candidates, 323 Black candidates, 261 Hispanic candidates, 112 Asian candidates, and 142 candidates who reported race or ethnicity as “other.”While multiple strategies were used to recruit candidates for the trial (including community outreach, referrals by trial investigators, paid advertisements, and more), White candidates were more likely to report referrals from a variety of sources, while Black, Hispanic, and Asian candidates were more likely to report being recruited by the study sites.The screening process for the AD4 trial included five visits completed within 90 days. A total of 1,683 participants were excluded based on their initial screening visit, which included cognitive testing and other assessments. Non-White participants were excluded more frequently at an initial screening than were White participants: 30.7% of Black participants, 26.8% of Asian participants, and 26.1% Hispanic participants were excluded from the trial during an initial screening compared with 16.2% of White participants. Non-Whites were also more likely to be excluded when amyloid was assessed.“The current results suggest that, even among the relatively small number of Hispanic and non-White participants recruited to the A4 trial, participan...
Source: Psychiatr News - Category: Psychiatry Tags: Alzheimer's disease clinical trials health disparities JAMA Network Open screening study recruitment Source Type: research